Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis

Chiara Citterio, Michela Baccini, Elena Orlandi, Camilla Di Nunzio and Luigi Cavanna _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:29801-29809. https://doi.org/10.18632/oncotarget.25639

Metrics: PDF 1967 views  |   HTML 4231 views  |   ?  


Chiara Citterio1, Michela Baccini2, Elena Orlandi1, Camilla Di Nunzio1 and Luigi Cavanna1

1Onco-Haematology Department, Hospital Guglielmo da Saliceto, 29121 Piacenza, Italy

2Department of Statistics, Informatics, Applications “G. Parenti”, Università di Firenze, 50134 Florence, Italy

Correspondence to:

Luigi Cavanna, email: [email protected]

Keywords: pancreatic cancer; second-line chemotherapy; oxaliplatin; irinotecan; gemcitabine based chemotherapy

Received: April 24, 2018     Accepted: June 04, 2018     Published: July 03, 2018


Guidelines for treatment of metastatic pancreatic cancer recommend a second line based on Fluoropyrimidine (FP) alone or in combination with Oxaliplatin (OXA) or Irinotecan (IRI) after a first line treatment based on Gemcitabine (GEM). We conducted a Bayesian network meta-analysis to compare currently available therapies to treat metastatic pancreatic cancer in the second line, considering as efficacy measures overall survival (OS) and progression free survival (PFS). Published randomized trials were identified using electronic databases (MEDLINE, PubMed, https://clinicaltrials.gov/ and American Society of clinical oncology). 8 studies met the inclusion criteria for a total of 1,587 patients and 7 different therapeutic schemes. The results suggested that the use of IRI-FP-Folinic Acid scheme in the second-line treatment of metastatic pancreatic cancer may offer a benefit in terms of OS and PFS for patients not previously treated with these drugs.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25639